Sanofi SA has raised $11.7 billion from the sale of most of its equity holding in Regeneron Pharmaceuticals Inc, a close partner and co-developer of some of the French company’s most successful products. These include the anti-inflammatory drug Dupixent (dupilumab) which has been approved in the US for four indications. The transaction closed on 29 May.
